273 related articles for article (PubMed ID: 27613177)
1. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.
Al-Awadhi A; Adekile A; Marouf R
J Thromb Thrombolysis; 2017 Jan; 43(1):117-123. PubMed ID: 27613177
[TBL] [Abstract][Full Text] [Related]
2. Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.
Al-Awadhi A; Adekile A; Marouf R
Acta Haematol; 2021; 144(2):182-189. PubMed ID: 32987383
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
[TBL] [Abstract][Full Text] [Related]
4. ADAMTS-13-VWF axis in sickle cell disease patients.
Ladeira VS; Barbosa AR; Oliveira MM; Ferreira LGR; de Oliveira Júnior WV; de Oliveira Renó C; Reis EA; Chaves DG; Dusse LMS; Dos Santos HL; de Barros Pinheiro M; Rios DRA
Ann Hematol; 2021 Feb; 100(2):375-382. PubMed ID: 33404693
[TBL] [Abstract][Full Text] [Related]
5. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease.
Zhou Z; Han H; Cruz MA; López JA; Dong JF; Guchhait P
Thromb Haemost; 2009 Jun; 101(6):1070-7. PubMed ID: 19492149
[TBL] [Abstract][Full Text] [Related]
6. ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait.
Al-Awadhi AM; Jadaon MM; Al-Jafar HA; Al-Wazzan HJ
Acta Haematol; 2011; 125(3):160-6. PubMed ID: 21196718
[TBL] [Abstract][Full Text] [Related]
7. Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.
He S; Cao H; Magnusson CG; Eriksson-Berg M; Mehrkash M; Schenck-Gustafsson K; Blombäck M
Thromb Res; 2001 Aug; 103(3):241-8. PubMed ID: 11672586
[TBL] [Abstract][Full Text] [Related]
8. Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Karakaya B; Tombak A; Serin MS; Tiftik N
Hematology; 2016 Jun; 21(5):295-9. PubMed ID: 26872106
[TBL] [Abstract][Full Text] [Related]
9. Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism.
Edvardsen MS; Hansen ES; Ueland T; Aukrust P; Brækkan SK; Morelli VM; Hansen JB
J Thromb Haemost; 2023 May; 21(5):1227-1237. PubMed ID: 36736832
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.
Mannucci PM; Capoferri C; Canciani MT
Br J Haematol; 2004 Jul; 126(2):213-8. PubMed ID: 15238142
[TBL] [Abstract][Full Text] [Related]
11. ADAMTS13 activity in sickle cell disease.
Schnog JJ; Kremer Hovinga JA; Krieg S; Akin S; Lämmle B; Brandjes DP; Mac Gillavry MR; Muskiet FD; Duits AJ;
Am J Hematol; 2006 Jul; 81(7):492-8. PubMed ID: 16755558
[TBL] [Abstract][Full Text] [Related]
12. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.
Chen J; Hobbs WE; Le J; Lenting PJ; de Groot PG; López JA
Blood; 2011 Mar; 117(13):3680-3. PubMed ID: 21300978
[TBL] [Abstract][Full Text] [Related]
13. Smoking, von Willebrand factor and ADAMTS-13 in healthy males.
Al-Awadhi AM; Jadaon MM; Alsayegh FA; Al-Sharrah SK
Scand J Clin Lab Invest; 2012 Dec; 72(8):614-8. PubMed ID: 23020229
[TBL] [Abstract][Full Text] [Related]
14. The activity of the von Willebrand factor cleaving protease ADAMTS-13 in newborn infants.
Schmugge M; Dunn MS; Amankwah KS; Blanchette VS; Freedman J; Rand ML
J Thromb Haemost; 2004 Feb; 2(2):228-33. PubMed ID: 14995983
[TBL] [Abstract][Full Text] [Related]
15. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
[TBL] [Abstract][Full Text] [Related]
16. Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty.
Bander J; Elmariah S; Aledort LM; Dlott J; Stelzer P; Halperin JL; Kini AS; Sharma SK
Thromb Haemost; 2012 Jul; 108(1):86-93. PubMed ID: 22627470
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand Factor Adhesive Activity and ADAMTS13 Protease Activity in HIV-1-Infected Men.
Graham SM; Chen J; Le J; Ling M; Chung DW; Liles WC; López JA
Int J Med Sci; 2019; 16(2):276-284. PubMed ID: 30745808
[No Abstract] [Full Text] [Related]
18. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.
Guo R; Yang J; Liu X; Wu J; Chen Y
J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28374895
[TBL] [Abstract][Full Text] [Related]
19. Contribution of ADAMTS13-independent VWF regulation in sickle cell disease.
Hunt RC; Katneni U; Yalamanoglu A; Indig FE; Ibla JC; Kimchi-Sarfaty C
J Thromb Haemost; 2022 Sep; 20(9):2098-2108. PubMed ID: 35753044
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
Molvarec A; Rigó J; Bõze T; Derzsy Z; Cervenak L; Makó V; Gombos T; Udvardy ML; Hársfalvi J; Prohászka Z
Thromb Haemost; 2009 Feb; 101(2):305-11. PubMed ID: 19190814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
